High-throughput sequencing technologies have become fundamental for the identification of disease-causing mutations in human genetic diseases both in research and clinical testing contexts.
Introduction
The identification of human disease-causing mutations has relied for decades on Sanger sequencing and pre-screening technologies such as Single Strand Conformational Polymorphism (SSCP) or Denaturating Gradient Gel Electrophoresis (DGGE). This process was very slow and costly especially when genetic heterogeneity occurred. More importantly, it was difficult to apply this approach to large genes such as DMD (79 exons) or TTN (363 exons). With the rapidly developing high throughput solid phase sequencing technologies also known as Next Generation Sequencing (NGS), the strategy of gene hunting and diagnosis has drastically improved. In fact, in less than ten years, these NGS technologies have moved from gene panel sequencing (100 Mb for the Roche GS FLX system) to whole genome sequencing (1500 Gb for the Illumina HiSeq4000) and from research context only to clinical practice. The limitation is no longer the sequencing of one, many or all genes, but rather the sequence analysis and interpretation. Traditionally, scientists were afforded the luxury to develop expertise in a limited number of disease genes over a significant period of time.
Unfortunately, they are now facing the daunting "all genes data deluge" (Schatz and Langmead This article is protected by copyright. All rights reserved. 2013) where the expectation is to understand and interpret the suite of genes and their network of interactions implicated in disease. This next generation sequencing revolution now relies heavily on the field of bioinformatics, its tools, methods and analysis strategies to gather, store, analyze and mine the data in order to make informed decisions.
Despite the tens of thousands of exomes and genomes that have been studied (for instance, Exome Aggregation Consortium (ExAC), Cambridge, MA (URL: http://exac.broadinstitute.org), we have only a limited understanding of the molecular mechanisms underpinning the human genome variability, especially in the context of rare human genetic diseases (see article from Collod-Béroud et al. in this issue) . In fact, most disease-causing mutations are private (specific to a family) and the availability of functional tests to demonstrate their pathogenicity is limited. As such, distinguishing neutral mutations from disease-causing ones is challenging. This is even amplified for rare diseases, which are defined in Europe as conditions with a frequency below 1:2000 (Regulation (EC) N°141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products, http://ec.europa.eu/health/files/eudralex/vol-1/reg_2000_141/reg_2000_141_en.pdf). It is estimated that more than 7,000 rare human genetic diseases exist (https://globalgenes.org/rarediseases-facts-statistics/), most of them being very rare. A review from Orphanet (http://orphadata.org/data/xml/en_product2_prev.xml) revealed that the majority consist of a handful of published reports describing a few individuals with a previously unidentified genetic syndrome, see Figure 1 .
Despite this apparent low number of affected individuals, it is estimated that all together the rare diseases account for up to 6-8% of the global population having a strong socio-economic impact (http://www.ema.europa.eu). To diagnose most of these rare diseases by 2020, the International Rare Diseases Research Consortium (IRDiRC) was launched in April 2011. It supports international collaboration and data sharing (Thompson et al. 2014) as well as large scale sequencing projects This article is protected by copyright. All rights reserved. (Turner et al. 2015) . At the time of writing this manuscript, the cumulative number of new genes linked to rare diseases was 3,350 with 1,000 identified between 2010 and 2014, while 350 new rare diseases were described during this period (http://irdirc.org). Most of these genes have been identified as a result of both the revolution of NGS and advanced bioinformatics techniques.
In contrast, this success is tempered by clinical exome diagnosis which has a success rate of only 26% (Yang et al. 2013 ). This relatively low success rate may be due to a number of factors, namely: a) technical limitations such as the absence of the disease-causing mutation in the captured DNA; b) a poor capture of some exonic regions (GC-reach regions); c) a low sequencing depth; c) a poor sequencing quality of read extremities; d) a mutation type not compatible with NGS technologies such as triplet expansion or large structural genomic variation (Gilissen et al. 2012 ); e) limitation of the bioinformatics data analysis pipeline; f) presence of pseudogenes or repeated regions, which may lead to inadequate mapping and wrong calling of mutations (false positives); g) limitation of the mapping process as no "gold standard" exist and a compromise has to be made between speed and accuracy, or h) wrong annotation in databases which may lead to misinterpretation of a diseasecausing mutation.
The objective of this paper is to review the critical steps of variant annotations and filtration in order to guide users to collect the most appropriate elements related to each mutation and apply the proper filtration options to rapidly select a handful of candidate disease-causing mutations for downstream validation.
Variants annotation
The variant annotation process places mutations identified by the variant calling step (see Beltran et al. in this issue) into their biological context. This step is a requirement for the identification of variants of interest based upon a combined filtration of the collected data from one or multiple samples.
The main objective of this process is to gather substantial information at the variant and the gene levels. This will include the variants' data quality, their localization at the genomic, gene and transcripts levels, their genotype, their frequency in the general population, their impact at the mRNA and protein levels, the conservation among species of the affected protein residues, the variant pathogenicity prediction and reported associations with diseases. At the gene level, they include the gene function, its spatiotemporal expression pattern, its involvement in various pathways and its involvement in various phenotypes/diseases.
Annotations at the variant level
Currently, several methods are available for variant quality assessment depending on the variant calling tool such as UnifiedGenotyper GATK and HaplotypeCaller GATK (McKenna et al. 2010) , SamTools (Li et al. 2009) or Platypus (Rimmer et al. 2014) . These bioinformatics tools provide two scores: i) the variant quality score or the probability that this variation is real. It is provided as a Phred quality score (Q score) (Ewing and Green 1998) to assess the probability that a given base is called incorrectly; and ii) the genotype quality score, which is also a Phred quality score to assess the probability that the given genotype is incorrect.
The description of the localization of the mutation includes various stages. The first stage is the genomic coordinates of the variation and is dependent of the version of Human Genome assembly, currently GRCh37 or GRCh38. The second stage is the localization at the gene and transcripts level. It is dependent of the selected annotation of the human reference genome. It is provided by Ensembl, the University of California Santa Cruz (UCSC), or the National Center for Biotechnology Information (NCBI). As demonstrated by Zhao et al. these annotations strongly differ at the transcript level with This article is protected by copyright. All rights reserved. only 53% of junction reads mapping at the same genomic location depending of the used gene model (Zhao and Zhang 2015) . It is thus usually recommended for protein coding genes to use the Consensus Coding Sequence (CCDS), which is the result of a collaborative effort to maintain a dataset of protein-coding regions that are identically annotated on the human and mouse reference genome assemblies. CCDS are consistently represented by the NCBI, Ensembl, and UCSC Genome Browsers (Pruitt et al. 2009 ). When combining data from different sources, it is highly recommended to use annotations performed using the same reference genome.
Once the genomic coordinates have been determined, the HGVS nomenclature is usually used to name the mutations at the cDNA level for all transcripts and protein level for coding genes. Once again, the translation from a genomic nomenclature to a cDNA nomenclature may result in differences based on the variant caller and the annotation tool. This is especially true for insertions and deletions in a repeated sequence. It may thus be interesting to control mutations nomenclature after the initial annotation step using a system able to correct such errors. One such tool is the Variant Effect Predictor from Ensembl (VEP) (Yates et al. 2015) . In an attempt to evaluate the impact of functional annotation using various reference systems and tools, McCarthy et al. quantified the extent of differences in annotation of 80 million variants from a whole-genome sequencing study.
They compared results from the ANNOVAR and VEP software using REFSEQ and ENSEMBL transcripts. They reported only 44% agreement in annotations for putative loss-of-function variants using ANNOVAR. They also support data from Zhao et al. (Zhao and Zhang 2015) showing that the splicing variants were the category with the greatest discrepancy. They concluded that the annotation step must be considered carefully, and that a conscious choice should be made to select transcript set and software for annotation (McCarthy et al. 2014) .
Variant frequency
This article is protected by copyright. All rights reserved.
Another key annotation element is the frequency of the variant in the general population. If ideally this general population should match the sample's origin, it is usually not available and data is captured from large scale projects such as the 1000 genome project (1000 Genomes Project , dbSNP (Sherry et al. 2001) , the EVS (http://evs.gs.washington.edu/EVS/) or the EXAC consortium (Lek et al. 2015) . It is important to recognise that these datasets are not mutually exclusive as there is significant overlap and should therefore not be simply combined to extrapolate a global frequency. In addition, these datasets are not representative of a global population per se as they contain "assumed to be healthy" individuals and samples from selected individuals with a particular condition. Note that laboratories, which routinely perform high-though put sequencing usually build internal frequency databases to exclude potential artefacts.
Variant nomenclature and localization
The annotation of the impact of the DNA mutation at the mRNA and the protein levels is complex. If the consequence at the protein level is easy to predict and report using the HGVS nomenclature (p.), it is only a prediction and should be considered as such. For example, a frameshift mutation predicted to result in a premature termination codon and therefore to a shorter protein, usually does not exist in reality because of the nonsense mediated decay phenomenon (Miller and Pearce 2014) . Another example is the prediction of a protein harboring a missense mutation that indeed does not exist as its primary impact is at the mRNA level as exemplified by the c.2167G>A
(p.Asp723Asn) of the FBN1 gene that lead to the exon 17 skipping (Evangelisti et al. 2010) . The impact of mutations at the mRNA level is even less documented as it is annotated as splicing mutation if localized in the donor or acceptor splice site regions, while the splicing machinery recognizes many signals such as exonic splicing enhancers and silencers and is considered as one of the most complex process of the cell (Nilsen 2003) . Only few annotation tools are now including data from the Human Splicing Finder system that provides predictions for the impact of any mutation on all splicing signals (Desmet et al. 2009 ). The ANNOVAR system provides splice sites effect predictions by AdaBoost and Random Forest from dbscSNV (Wang et al. 2010) . The VEP system integrates various modules allowing to run external algorithms such as MaxEntScan (Yeo and Burge 2004) , GeneSplicer (Pertea et al. 2001) or the dbNSFP (Liu et al. 2016 ) for splice sites effect predictions.
Affected protein residue annotation
The next annotation for variations is the conservation of affected protein residues. This information is usually restricted to single nucleotide variations that may result in missense mutations. It could be used as the result of selection pressure to maintain a specific amino acid at a given position because of its importance for the structure or the function of the protein. Typically, the higher the conservation, the higher the probability that a missense could impact the protein function. Most annotators are using conservation data extracted from the dbNSFP (Liu et al. 2016 ) that colligate data from PhyloP (Pollard et al. 2010) , PhastCons (Siepel et al. 2006) , GERP++ (Davydov et al. 2010) and Siphy (Garber et al. 2009 ). This gives access to conservation data from 27, 46 and 100 species, respectively, when using the GRCh37/38 reference genome.
Variant pathogenicity
Variants are also annotated for their potential pathogenicity using multiple algorithms and systems.
Most annotator systems provide access to the following predictors: SIFT (Sim et al. 2012 ) Polyphen2 (Adzhubei et al. 2010) , LRT (Chun and Fay 2009) , MutationTaster (Schwarz et al. 2014 ), Mutation Assessor (Reva et al. 2011) , FATHMM (Shihab et al. 2013 ), MetaSVM and MetaLR (Dong et al. 2015) , CADD (Kircher et al. 2014) , VEST3 (Carter et al. 2013) , PROVEAN (Choi et al. 2012) , fitCons (Gulko et al. 2015) , fathmm-MKL (Shihab et al. 2015) , and DANN (Quang et al. 2015) . Only the VarAFT annotator (http://varaft.eu) provides annotations from the most efficient predictor for cDNA substitutions: UMD-Predictor (Salgado et al. 2016 ).
The final annotation at the variant level corresponds to its association with diseases. This information is usually extracted from various databases such as ClinVar (Landrum et al. 2014 ), This article is protected by copyright. All rights reserved.
COSMIC (Forbes et al. 2015) , UNIPROT (UniProt Consortium 2014) or HGMD (Stenson et al. 2003) . It is important to keep in mind that the quality of these associations is highly variable and that some resources are not freely available.
Annotations at the gene level
As many variations are new or lacking annotation, it is useful to access data at the gene level. Global functional information is provided by the Gene Ontology at the cellular component, molecular function and biological process levels (Gene Ontology Consortium 2015) . Additionally, data from tissue expression can be obtained from the Genotype Tissue Expression resource (GTEx) (Carithers et al. 2015) , the Gene Expression Atlas (Petryszak et al. 2016) and organism model databases such as the Mouse Genome Institute (Bult et al. 2016) . Unfortunately, the ability to integrated this data is not available for most annotators and often requires developing specific plugins such as the VEP annotator GXA.pm plugin to gather data from the Gene Expression Atlas.
Another level of genes annotation is their involvement in various pathways, these data can be found in BioCarta (Nishimura 2001) , the Pathway Interaction Database (PID) (Schaefer et al. 2009 ), the Reactome (Fabregat et al. 2016) , the WikiPathways (Kutmon et al. 2016) , and KEGG (Kanehisa et al. 2016 ). Despite their utility for gene hunting, the information captured in these tools are not automatically incorporated during the annotation process. They are only available through external links.
As for annotations at the variant level, it is important to capture the phenotypes associated to mutations from a particular gene. The Online Mendelian Inheritance in Man (OMIM) resource is providing such information (Amberger et al. 2014) . Other resources such as ClinVar, HGMD might also be used as part of the annotation process.
Annotation software
This article is protected by copyright. All rights reserved. Different types of annotation software are available either through command line, webservices or web interface. They require data in different format, most allowing direct annotation of VCF files.
They are compatible with either a single or multiple release versions of the human reference genome and allow annotation of SNP, Indels and CNV for only a limited number. As discussed, no system is providing annotations at all levels (Table 1) . To easily handle annotations at the variant and gene levels most of the systems rely on the dbNSFP database developed for functional prediction and annotation of all potential non-synonymous single-nucleotide variants in the human genome (Liu et al. 2016 ).
Selection of potential disease-causing mutations
Once annotations at the gene and variant levels have been performed, the user needs to reduce the significant number of variations (usually in the tens of thousands) to a small, manageable number of putative candidate disease-causing mutations for further experimental validation. This filtering process is likely the most critical process of NGS analysis. The aim is to combine filtration criteria to exclude spurious variants by taking into account various parameters such as: the mode of inheritance, the disease frequency, the pathogenicity prediction of variations, the gene expression pattern, known relations between the observed phenotype and gene mutations, and so forth.
Currently, as there is no gold standard describing an optimized filtration process for all situations, there are two options to proceed. Option one is to employ a semi-automatic prioritization systems such as eXtasy (Sifrim et al. 2013) , OMIM Explorer (James et al. 2016) or Exomiser (Smedley et al. 2015) . This approach is proven to be very useful in situations where the phenotype is clearly described (mostly available in clinical diagnostic context) using the proper ontology such as the Human Phenotype Ontology (HPO) (Köhler et al. 2014) or the disease name (Amberger et al. 2014) , as well as for gene hunting for the most advanced systems such as Exomiser and Phenolyzer .
The alternate option is to adopt a fully manual prioritization procedure based on expert knowledge related to the disease phenotype and genes functions. This approach is greatly facilitated by the use of user friendly filtration tools such as VarAFT (http://varaft.eu), FM Filter (Akgün et al. 2016 ),
VarSifter (Teer et al. 2012) , ExomeSuite (Maranhao et al. 2014) , wKGGSeq (Li et al. 2015) or customizable filtration tools that require advance knowledge in informatics as they must be used through command-line scripts such as ANNOVAR (Wang et al. 2010) or GEMINI (Paila et al. 2013 ).
The semi-automatic prioritization systems use different prioritization algorithms and data. As reported by Rehm et al., the choice of the filtering process may differ across case types and requires a high level of expertise in genetics and molecular biology (Rehm et al. 2013 ). We will here describe the various steps that may be combined for manual prioritization. Table 2 lists some filtration systems and available filtration options.
Mode of inheritance
The initial step is linked to the mode of inheritance allowing the selection of either homozygous, heterozygous or compound heterozygous mutations either inherited or de novo. This selection process is facilitated when multiple samples from the family (trio) or the patient (somatic events) are available. As reported by Farwell et al., the diagnostic rate is higher among families undergoing a trio Whole Exome Sequencing (WES) (37%) as compared to a singleton (21%) (Farwell et al. 2015) .These data were confirmed by Sawyer et al., reporting WES success rates of 23% for singletons, 32% for sibling pairs, and 34% for families (Sawyer et al. 2016) . For instance, in the case of recessive conditions, the disease-causing mutations mainly correspond to compound heterozygous mutations for non-consanguineous families except for situations where a mutations is frequent in the population such as the ∆F508 mutation (NM_000492.3: c.1521_1523del) of the CFTR gene (Alfonso- Sánchez et al. 2010) and to homozygous mutations for consanguineous families. The most advanced systems such as VarAFT allow supporting of these hypotheses in difficult missing data contexts where one parent might be not sufficiently covered in one specific region.
Mutation localization
The mutation localization is usually the second parameter. Variants from key genomic regions (exons, splice sites) are usually selected while variants from other genomic regions (3' and 5'UTR, intronic regions) are discarded. In fact, if pathogenic mutations have been reported in 3' and 5' UTR, they mainly correspond to trinucleotide repeat expansions as illustrated by Spinocerebellar Ataxia type12 (#604326) and Fragile X tremor/Ataxia syndrome (#300625) for 5'UTR and Spinocerebellar Ataxia type 8 (#608768), Myotonic Dystrophy 1 (#160900) or Huntington disease like 2 (#606438) for 3' UTR (Richards et al. 2013) . Nevertheless, it is important to keep in mind that these repeat expansions are not captured by most NGS technologies such as Illumina or Proton that generate only short reads. Other variants from these regions may be subsequently analyzed when no meaningful result is obtained.
Mutation type
It is well recognized that not all mutation types might result in an equal effect on proteins and diseases. Thus, it is usually considered that nonsense mutations as well as frameshift mutations have a strong impact while at the other end of the spectrum, synonymous changes usually have no impact at the protein level but may affect mRNA maturation. If in the past, synonymous changes have been frequently filtered-out, they are today conserved during this selection process. It is recommended to remove only variants belonging to the "unknown" or "in-frame deletions and insertions" mutation types. Other variants will be excluded through other filtration process such as pathogenicity predictions and frequency.
Mutation frequency
As most genetic diseases are rare, mutation frequency could be used to exclude frequent variations (see paper from Collod et al. in this issue). Ideally, this information should be captured from a matched population. In practice it is rarely feasible and users rely on frequencies from 1000 genome project (1000 Genomes Project , dbSNP (Sherry et al. 2001) , the EVS (http://evs.gs.washington.edu/EVS/) or the EXAC consortium (Lek et al. 2015) as mentioned in the annotation section. Additionally, some large scale sequencing analysis project, such as ExAC, allow at the same time to combine the frequency data with the level of coverage observed in order to provide an accurate reflection of a specific variant within a population. Depending on the mode of inheritance and the frequency of the disease, it is possible to calculate the theoretical threshold of the disease-causing mutation frequency under the assumption that all observed cases harbor a single mutation. For example, for an autosomal dominant disease with a frequency of 1:10000, the allele frequency threshold is 0.01% while for an autosomal recessive disease with the same frequency, the threshold is 1%. However, obtaining this information for genetically heterogeneous disorders with overlapping clinical phenotypes might be challenging.
Pathogenicity predictions
During the last few years, various systems have been developed to predict the pathogenicity of mutation from human genes. They contain predictions for synonymous and non-synonymous changes, mutations potentially affecting mRNA splicing motifs as well as regulatory regions including miRNA binding sites, transcription Factor binding sites (Boyle et al. 2012) , chromatin states (Ward and Kellis 2016) and non-coding regions (Kircher et al. 2014; Ritchie et al. 2014) . It is essential for a critical interpretation of results to understand the strengths and limitations of each system. For example, predictions of the impact of mutations on splice sites and branch points are very accurate, This article is protected by copyright. All rights reserved. while they are less efficient for splicing auxiliary splicing sequences (Desmet et al. 2010) . Similarly, predictions of the pathogenicity of missense mutations could be performed with a wide range of systems with accuracy ranging from 72% to 85% on a dataset of 17,329 variants (Salgado et al. 2016 ). Some authors have proposed to integrate individual predictions into meta systems such as PON-P (Olatubosun et al. 2012 ) and Condell (González-Pérez and Lopez-Bigas 2011) but consensus is only achieved for a subset of mutations, which are often relatively easy to predict. Therefore, it is better to use a limited set of predictors for filtration rather than combining all predictions, which may result in many situations with discrepancies between predictors. For example the NM_022124.5:c.4488G>C (p.Gln1496His) mutation of the CDH23 gene has been reported as a pathogenic mutation (Bolz et al. 2001) . Only the CADD, UMD-Predictor and Mutation Taster systems predicted this variant as pathogenic while the SIFT, Polyphen2, Condel, Provean and Mutation Assessor systems predicted it as a non-pathogenic mutation. In Figure 1 a Venn diagram is presented highlighting the predictions from the most frequently used predictors on a subset of randomly chosen 5,000 variations from the Uniprot dataset (Salgado et al. 2016) . The 6 predictors reach consensus for only 3074 (61.5%) of variants, while if using only the 2 most efficient systems (UMDPredictor and CADD), consensus is achieved for 4275 (85.5%) variants.
Functional evidences
Numerous studies have resulted in functional annotations of genes in various species and a specific ontology has been developed to described these functional annotations: Gene Ontology (Gene Ontology Consortium 2015) . In parallel, genes have been classified in various pathways (Nishimura 2001; Fabregat et al. 2016; Kanehisa et al. 2016 ) in order to capture relationships and facilitate gene hunting. Furthermore, spatiotemporal expression patterns have been established for many genes in various species using a number of different high throughput techniques such as in situ hybridization (Tomancak et al. 2002) , micro arrays (Petryszak et al. 2016 ) and RNA-seq (GTEx Consortium 2013).
Unfortunately, despite the importance of these data they are usually not available for filtration.
Previous description in databases
As mentioned in the beginning of this section, the description of mutations might be helpful for variant prioritization. In addition to variants' frequency, the availability of curated and previously annotated data is of primary importance. Such data can be found in Locus Specific DataBases (LSDB) such as LOVD (Fokkema et al. 2005) , UMD (Béroud et al. 2005 ) and others (http://www.hgvs.org/locus-specific-mutation-databases) or Core databases such as HGMD (Stenson et al. 2003) , ClinVar (Landrum et al. 2014) , OMIM (Amberger et al. 2014) , Uniprot (UniProt Consortium 2014) or RDRF (Bellgard et al. 2014 ). These annotations are of different qualities due to different curation modes ranging from full curation by experts to direct submission without review.
In this context it is important to do not consider annotations as definitive answers but rather as evidences of causality. These data are usually not available for filtration but as additional annotations. Figure 3 proposes a standard filtration flowchart to identify disease-causing mutations in a context of a trio analysis for the recessive mode of inheritance. The samples were described by Kamphans et al. (Kamphans et al. 2013 ) and correspond to a family with one daughter (sample ID #464) affected by Mabry syndrome and her two healthy parents (samples ID #466 and 467). The flowchart is composed of 5 steps, however, the fifth step could be divided into functional evidences and previous description in databases. As illustrated, the availability of the trio allows a drastic reduction of the candidate variations/genes during the first step where the compound heterozygous hypothesis has been selected. Alternative hypothesis such as homozygous mutation in the daughter with heterozygous parents for the mutation as well as more complex hypothesis where one of the two parents has insufficient sequencing quality resulting in missing data, should also be investigated in parallel (see below). In the second step, only mutations localized in exons and their vicinity are conserved. This parameter corresponds to the most frequent situation and can be adjusted on a case by case basis especially for genes where mutations in UTR regions have been reported with a high frequency. The third step uses frequency information from the 3 most popular databases (EVS, 1000 genomes and ExAC) even if they overlap (see above). The frequency threshold can be adjusted if the disease frequency is known or arbitrarily fixed to 1% in case of a recessive condition. For the fourth step, we selected only predictions from the UMD-Predictor and CADD systems. Based on user experience, the selection of predictors might vary. Note that in this use case, one of the two diseasecausing mutations from the PIGO gene is a missense variation (NM_032634, c.2869C>T, p.Leu957Phe) for which pathogenicity predictions are available, the second one being a frameshift deletion (NM_032634, c.2355dupC). It is important to note that in this case, the use of more predictions algorithms might have resulted in loss of this candidate gene as this mutation is predicted as being non-pathogenic by SIFT and Mutation Taster. The final step corresponds to the collection of additional evidence. Here only two candidate genes with compound heterozygous mutations were present: the AFF1 and the PIGO genes. After collection of evidences from OMIM, the PIGO gene can be selected as the only hypothesis compatible with the phenotype.
Proposed Filtration Flowcharts
In this use case the disease-causing mutations were efficiently captured which is only true for a limited number of situations as reported by the clinical exome diagnosis success rate of only 26% (Yang et al. 2013 ). For the negative cases it is important to consider the following hypothesis.
Hypothesis 1: poor sequence quality in one sample leading to missing data. Only few filtration tools allow the handling of missing data and might lead to candidate exclusion. This article is protected by copyright. All rights reserved. This approach revealed a significant power increase for gene discovery, as demonstrated through the studies of exome data of Autism Spectrum Disorder (ASD) (He et al. 2013 ) and might be useful in other situations.
Hypothesis 3: involvement of a large rearrangement or Copy Number Variation (CNV). It is recognized that CNV are frequently involved in human genetic diseases with the archetype of Duchenne Muscular Dystrophy where they account for up to 60% of mutations (Bladen et al. 2015) .
These CNV might now be captured from WES data and various tools are available (Nam et al. 2016) .
It is therefore important to combine this information with SNV.
Hypothesis 4: some variations could be missed by the WES technologies because they are localized outside captured regions (deep intronic, regulatory regions).
Hypothesis 5: bioinformatics pipelines limitations. The alignment process could lead to wrong reads' mapping because of high homology between various genomic regions. This might end up with wrong variant calling resulting in false positives or false negatives. In addition, repeated sequences can not be aligned and prevent mutation identification as it is the case for trinucleotide repeats, which are responsible for many human diseases (Keogh and Chinnery 2013) .
Discussion
High throughput sequencing technologies that include Whole Exome Sequencing generate a high number of sequence variations in all individuals. Identifying disease-causing mutations among this large amount of data is a significant challenge. In this paper, we described the annotation and filtration steps that are mandatory to rapidly end up with a handful of disease-causing candidate mutations for further analysis. Even if the success rate is still limited, these technologies have a strong potential to diagnose most human monogenic diseases. To do so, it is first critical to understand the advantages as well as the limits of the annotation and filtration systems as incorrect or incomplete annotations can cause scientists both to overlook potentially disease-relevant DNA mutations as well as potentially dilute interesting mutations into a pool of false positives.
Additionally, the filtration process requires experts in order to efficiently define hypothesis and successfully apply filtration tools. Finally, a close collaboration with clinicians is also a pre-requisite to avoid misclassification of patients that often prevent the disease-causing mutation discovery as experienced by many research teams.
Despite the availability of many bioinformatics systems for annotation and filtration, there is no gold standard available to solve every situation. Some semi-automatic prioritization systems taking into account genotypes and phenotypes are now available and could be of interest for specific situations (Sifrim et al. 2013; Smedley et al. 2015; James et al. 2016) . However, most users typically use a combination of annotation and filtration systems. This can be done manually through dedicated systems (Teer et al. 2012; Maranhao et al. 2014; Li et al. 2015; Akgün et al. 2016) or using frameworks such as the Galaxy (Goecks et al. 2010) and Yabi (Hunter et al. 2012 ). The latter is flexible enough to allow any combination of software tools and data into sophisticated analysis procedures. In addition, the generated workflows can be easily shared and adjusted. Despite these strong benefits, these systems require not only bioinformatics skills but also a full understanding of the parameters of each step to reach efficiency and are therefore not fully adopted.
With the future switch to whole genome sequencing, additional challenges will emerge such as the handling of very large datasets and the interpretation of new mutation types: i) deep intronic mutations; ii) regulatory region mutations; iii) mutations found in non-coding genes (lncRNA (Wapinski and Chang 2011) , T-UCR, circular ncRNA, small nucleolar RNA and miRNA (Esteller 2011) and iv) mutations reported in extra-genic regions (Dickel et al. 2013) . As reported by Berg et al., a significant obstacle to implementing WGS is the huge amount of information that will be generated even if they consider that only a small subset might be relevant for interpretation due to a lack of knowledge (Berg et al. 2011) . Nevertheless, it is anticipated that with the global adoption of WGS, more data will be generated and will contribute to the development of new bioinformatics tools and systems to facilitate their interpretation. If people often consider sequencing costs as the major barrier for WGS adoption, it is important to not only consider these costs but also human resources required for data interpretation. In fact, human resource needs for full clinical interpretation of WGS data remain considerable as described by Dewey et al. who reported that approximately 100 variants should be manually evaluated in each patient and that candidate disease causing mutation curation required at least one hour per variant (Dewey et al. 2014) .
It is reasonable to believe that during this WGS progressive adoption phase, most users will first benefit from better exonic regions coverage when compared to WES (Belkadi et al. 2015) . In this situation they might directly benefit from all annotation and filtration systems developed for WES data analysis and described here before the availability of innovative annotation and filtration systems for non-coding mutations. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved. 
